Overview Dividends

(RXRX) Recursion Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75629V1044

Drug Discovery Platform, Clinical-Stage Candidates

EPS (Earnings per Share)

EPS (Earnings per Share) of RXRX over the last years for every Quarter: "2020-09": null, "2020-12": -0.25, "2021-03": -1.33, "2021-06": -0.31, "2021-09": -0.28, "2021-12": -0.38, "2022-03": -0.33, "2022-06": -0.38, "2022-09": -0.35, "2022-12": -0.31, "2023-03": -0.34, "2023-06": -0.38, "2023-09": -0.43, "2023-12": -0.42, "2024-03": -0.39, "2024-06": -0.4, "2024-09": -0.34, "2024-12": -0.53, "2025-03": -0.5, "2025-06": -0.41, "2025-09": -0.36,
EPS Growth (3y CAGR): -7.49%
EPS Trend (3y Corr): -44.9%
Last SUE: 0.19σ
Qual. Beats: 0

Revenue

Revenue of RXRX over the last years for every Quarter: 2020-09: 0.862, 2020-12: 2.551, 2021-03: 2.5, 2021-06: 2.5, 2021-09: 2.5, 2021-12: 2.5, 2022-03: 5.299, 2022-06: 7.653, 2022-09: 13.053, 2022-12: 13.676, 2023-03: 12.134, 2023-06: 11.016, 2023-09: 10.102, 2023-12: 10.891, 2024-03: 13.491, 2024-06: 14.404, 2024-09: 26.082, 2024-12: 4.511, 2025-03: 14.745, 2025-06: 19.103, 2025-09: 5.175,
Revenue Growth (3y CAGR): -29.77%
Revenue Trend (3y Corr): -15.2%
Last SUE: -3.17σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 83.9%
Value at Risk 5%th 124%
Relative Tail Risk -9.99%
Reward TTM
Sharpe Ratio -0.08
Alpha -61.79
Character TTM
Hurst Exponent 0.404
Beta 2.557
Beta Downside 2.411
Drawdowns 3y
Max DD 75.73%
Mean DD 46.25%
Median DD 51.77%

Description: RXRX Recursion Pharmaceuticals November 10, 2025

Recursion Pharmaceuticals (NASDAQ:RXRX) is a clinical-stage biotech that combines high-throughput biology, chemistry, automation, and AI-driven data science to “industrialize” drug discovery. Its lead pipeline includes REC-994 (Phase 2 for cerebral cavernous malformation), REC-2282 (Phase 2/3 for neurofibromatosis type 2), REC-4881 (Phase 1b/2 for familial adenomatous polyposis and Phase 2 for AXIN1/APC-mutant cancers), REC-3964 (Phase 1 for Clostridioides difficile infection), and a preclinical RBM39 program targeting HR-proficient ovarian cancer. The firm maintains research collaborations with Bayer, Roche & Genentech, Takeda, the University of Utah, and the Ohio State Innovation Foundation.

As of the most recent quarterly filing (Q2 2024), Recursion reported a cash balance of roughly **$200 million**, giving it an estimated runway of 12–15 months at current burn rates (~$15 million per quarter). The company’s R&D spend has risen 38 % YoY, reflecting accelerated enrollment in its Phase 2/3 neurofibromatosis trial. In the broader biotech sector, AI-enabled drug discovery platforms have attracted **$4 billion+** of venture capital in 2023, suggesting a macro-level tailwind for firms that can demonstrate scalable hit-to-lead conversion metrics.

For a data-driven assessment of RXRX’s valuation dynamics, you may find it useful to explore ValueRay’s detailed analyst models, which break out the probability-weighted cash flows of each clinical asset.

RXRX Stock Overview

Market Cap in USD 2,257m
Sub-Industry Biotechnology
IPO / Inception 2021-04-16
Return 12m vs S&P 500 -43.0%
Analyst Rating 3.38 of 5

RXRX Dividends

Currently no dividends paid

RXRX Growth Ratios

Metric Value
CAGR 3y -25.57%
CAGR/Max DD Calmar Ratio -0.34
CAGR/Mean DD Pain Ratio -0.55
Current Volume 38814.8k
Average Volume 38326.8k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-715.5m TTM) > 0 and > 6% of Revenue (6% = 2.61m TTM)
FCFTA -0.32 (>2.0%) and ΔFCFTA 13.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 1284 % (prev 563.1%; Δ 720.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.32 (>3.0%) and CFO -441.2m > Net Income -715.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 4.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (447.0m) change vs 12m ago 58.18% (target <= -2.0% for YES)
Gross Margin -93.82% (prev 13.79%; Δ -107.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 4.10% (prev 8.93%; Δ -4.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -294.4 (EBITDA TTM -636.9m / Interest Expense TTM 2.43m) >= 6 (WARN >= 3)

Altman Z'' -12.24

(A) 0.40 = (Total Current Assets 714.1m - Total Current Liabilities 155.1m) / Total Assets 1.40b
(B) -1.41 = Retained Earnings (Balance) -1.97b / Total Assets 1.40b
warn (B) unusual magnitude: -1.41 — check mapping/units
(C) -0.67 = EBIT TTM -714.1m / Avg Total Assets 1.06b
(D) -5.48 = Book Value of Equity -1.93b / Total Liabilities 352.6m
Total Rating: -12.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 26.50

1. Piotroski 0.50pt
2. FCF Yield -26.68%
3. FCF Margin data missing
4. Debt/Equity 0.08
5. Debt/Ebitda 0.91
6. ROIC - WACC (= -85.79)%
7. RoE -72.74%
8. Rev. Trend -15.24%
9. EPS Trend -44.94%

What is the price of RXRX shares?

As of November 21, 2025, the stock is trading at USD 3.85 with a total of 38,814,763 shares traded.
Over the past week, the price has changed by -11.09%, over one month by -42.37%, over three months by -19.29% and over the past year by -36.26%.

Is RXRX a buy, sell or hold?

Recursion Pharmaceuticals has received a consensus analysts rating of 3.38. Therefor, it is recommend to hold RXRX.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 6
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RXRX price?

Issuer Target Up/Down from current
Wallstreet Target Price 6.3 63.6%
Analysts Target Price 6.3 63.6%
ValueRay Target Price 3.2 -18.2%

RXRX Fundamental Data Overview November 15, 2025

Market Cap USD = 2.26b (2.26b USD * 1.0 USD.USD)
P/S = 51.6622
P/B = 2.3202
Beta = 0.924
Revenue TTM = 43.5m USD
EBIT TTM = -714.1m USD
EBITDA TTM = -636.9m USD
Long Term Debt = 11.9m USD (from longTermDebt, last quarter)
Short Term Debt = 20.4m USD (from shortTermDebt, last quarter)
Debt = 82.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -577.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.68b USD (2.26b + Debt 82.4m - CCE 659.8m)
Interest Coverage Ratio = -294.4 (Ebit TTM -714.1m / Interest Expense TTM 2.43m)
FCF Yield = -26.68% (FCF TTM -448.0m / Enterprise Value 1.68b)
FCF Margin = -1029 % (FCF TTM -448.0m / Revenue TTM 43.5m)
Net Margin = -1644 % (Net Income TTM -715.5m / Revenue TTM 43.5m)
Gross Margin = -93.82% ((Revenue TTM 43.5m - Cost of Revenue TTM 84.4m) / Revenue TTM)
Gross Margin QoQ = -471.8% (prev -5.54%)
Tobins Q-Ratio = 1.20 (Enterprise Value 1.68b / Total Assets 1.40b)
Interest Expense / Debt = 1.01% (Interest Expense 833.0k / Debt 82.4m)
Taxrate = -0.00% (negative due to tax credits) (3000 / -162.2m)
NOPAT = -714.1m (EBIT -714.1m * (1 - -0.00%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.60 (Total Current Assets 714.1m / Total Current Liabilities 155.1m)
Debt / Equity = 0.08 (Debt 82.4m / totalStockholderEquity, last quarter 1.05b)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -577.5m / EBITDA -636.9m)
Debt / FCF = 1.29 (negative FCF - burning cash) (Net Debt -577.5m / FCF TTM -448.0m)
Total Stockholder Equity = 983.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.13% (Net Income -715.5m / Total Assets 1.40b)
RoE = -72.74% (Net Income TTM -715.5m / Total Stockholder Equity 983.7m)
RoCE = -71.72% (EBIT -714.1m / Capital Employed (Equity 983.7m + L.T.Debt 11.9m))
RoIC = -70.86% (negative operating profit) (NOPAT -714.1m / Invested Capital 1.01b)
WACC = 14.93% (E(2.26b)/V(2.34b) * Re(15.44%) + D(82.4m)/V(2.34b) * Rd(1.01%) * (1-Tc(-0.00)))
Discount Rate = 15.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 38.46%
Fair Price DCF = unknown (Cash Flow -448.0m)
EPS Correlation: -44.94 | EPS CAGR: -7.49% | SUE: 0.19 | # QB: 0
Revenue Correlation: -15.24 | Revenue CAGR: -29.77% | SUE: -3.17 | # QB: 0

Additional Sources for RXRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle